All Stories

  1. Editorial: Effectiveness and safety of ustekinumab in ulcerative colitis—Where we are now
  2. Enhancing Oral 5-ASA Effectiveness in Mild-to-Moderate Ulcerative Colitis through an H. erinaceus-Based Nutraceutical Add-on Multi-Compound: The “HERICIUM-UC” Two-Arm Multicentre Retrospective Study
  3. Bowel movement alterations predict the severity of diverticular disease and the risk of acute diverticulitis: a prospective, international st
  4. Impact of a Symbiotic Mixture on Moderate-to-severe Diverticular Disease of the Colon
  5. Ustekinumab in the Treatment of Inflammatory Bowel Diseases: Evolving Paradigms
  6. Clinical use of biologics for Crohn’s disease in adults: lessons learned from real-world studies
  7. Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study
  8. Ustekinumab in the Treatment of Inflammatory Bowel Diseases: Evolving Paradigms
  9. Diverticular Inflammation and Complication Assessment classification, CODA score and fecal calprotectin in clinical assessment of patients with diverticular disease: A decision curve analysis
  10. Prevalence and Natural History of Segmental Colitis Associated With Diverticulosis
  11. Ulcerative Colitis After Complicated Diverticulitis
  12. Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn’s disease: results from an Italian multicenter study
  13. Appropriateness of Proton Pump Inhibitor Prescription Evaluated by Using Serological Markers
  14. Microbiota Composition in Diverticular Disease: Implications for Therapy
  15. When to Perform a Colonoscopy in Diverticular Disease and Why: A Personalized Approach
  16. Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study
  17. Comparison of Performances of Adalimumab Biosimilars SB5, APB501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study
  18. Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study
  19. Diverticular Inflammation and Complication Assessment (DICA) Classification
  20. Comparison of Performances of Infliximab Biosimilars CT-P13 Versus SB2 in the Treatment of Inflammatory Bowel Diseases: A Real-Life Multicenter, Observational Study in Italy
  21. COVID-19 as a Trigger for De Novo Crohn’s Disease
  22. Prognostic performance of the ‘DICA’ endoscopic classification and the ‘CODA’ score in predicting clinical outcomes of diverticular disease: an international, multicentre, prospective cohort study
  23. Prevalence of gastro-esophageal reflux disease in suspected laryngo-pharingeal reflux unresponsive to proton-pump inhibitors
  24. Effectiveness and Safety of A Nutraceutical Formulation for the Treatment of Functional Dyspepsia in Primary Care
  25. Letter: ustekinumab for the treatment of post‐surgical and refractory Crohn's disease
  26. INTESTINAL MICROBIOME MODULATION DURING COVID-19: ANOTHER CHANCE TO MANAGE THE DISEASE?
  27. Anti-TNF-α Agents in Inflammatory Bowel Disease and Course of COVID-19
  28. COVID-19 infection in Crohn’s disease under treatment with adalimumab
  29. Covid-19 and the management of patients with inflammatory bowel disease: a practical decalogue for the post-pandemic phase
  30. Complicated diverticulitis mimicking colonic carcinoma: combined approach with endoscopy and budesonide
  31. Vedolizumab is effective and safe in real-life treatment of inflammatory bowel diseases outpatients: A multicenter, observational study in primary inflammatory bowel disease centers
  32. Role of Inflammation in the Pathogenesis of Diverticular Disease
  33. Long-term efficacy of rifaximin to manage the symptomatic uncomplicated diverticular disease of the colon
  34. Urinary metabolic profiling and symptomatic uncomplicated diverticular disease of the colon
  35. Rectal Dieulafoy lesion
  36. Effectiveness of golimumab in inducing remission and clinical response in outpatient ulcerative colitis
  37. Diverticulosis today: unfashionable and still under-researched
  38. Managing ambulatory ulcerative colitis patients with infliximab: A long-term follow-up study in primary gastroenterology centers
  39. Efficacy, safety, and applicability of outpatient treatment for diverticulitis
  40. Colonoscopy by nurse endoscopists: the right answer for the growing demand for colonoscopy in clinical practice?